LBA
MDNA

Letko, Brosseau & Associates’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Letko, Brosseau & Associates’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-120,000
Closed -$35.4K – 100
2023
Q3 		$35.4K Hold
120,000
– – ﹤0.01% 97
2023
Q2 		$57.8K Sell
120,000
-50,000
-29% -$30.9K ﹤0.01% 93
2023
Q1 		$107K Hold
170,000
– – ﹤0.01% 87
2022
Q4 		$77.9K Buy
170,000
+70,000
+70% +$42.8K ﹤0.01% 96
2022
Q3 		$83K Hold
100,000
– – ﹤0.01% 98
2022
Q2 		$116K Hold
100,000
– – ﹤0.01% 96
2022
Q1 		$128K Hold
100,000
– – ﹤0.01% 99
2021
Q4 		$163K Hold
100,000
– – ﹤0.01% 105
2021
Q3 		$277K Buy
+100,000
New +$248K ﹤0.01% 100

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Letko, Brosseau & Associates's MDNA Position: Q4 2023 in Review

Letko, Brosseau & Associates sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 120,000 shares — an estimated $35.4K sold.

Letko, Brosseau & Associates first reported a position in MDNA in Q3 2021 and held it in 9 quarters. The position peaked at $277K in Q3 2021. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Letko, Brosseau & Associates reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 120,000 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $35.4K.
  • Letko, Brosseau & Associates first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2021 and held it in 9 quarters.
  • Letko, Brosseau & Associates's Medicenna Therapeutics Corp. Common Shares position peaked at $277K in Q3 2021.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2023, filed 12 Feb 2024.